Richard J Perry,Arina Tamborska,Bhagteshwar Singh,Brian Craven,Richard Marigold,Peter Arthur-Farraj,Jing Ming Yeo,Liqun Zhang,Ghaniah Hassan-Smith,Matthew Jones,Christopher Hutchcroft,Esther Hobson,Dana Warcel,Daniel White,Phillip Ferdinand,Alastair Webb,Tom Solomon,Marie Scully,David J Werring,Christine Roffe,CVT After Immunisation Against COVID-19 (CAIAC) collaborators,Sara Al-Izzi,Aravindhan Baheerathan,Soma Banerjee,Gary Benson,Claudia Boshier,Sandeep Buddha,Nathan Burley,Ruaridh Cameron Smail,Arvind Chandratheva,Pavel Chudakou,Philip Clatworthy,Alasdair Coles,Thomas Cox,Ranjit Dasgupta,Richard Davenport,Darrell Devine,Stephen Fenlon,Carolyn Gabriel,Rita Ghatala,Claire Hall,Milan Hargovan,Kirsty Harkness,Ian Harvey,Lucy Hicken,Laura Howaniec,Abubaker Ibnouf,Luis Idrovo,Gordon Ingle,Yong Kyan Lee,Ailidh Lang,Simon McBride,Malcolm McLeod,Ruth Medlock,Puja Mehta,Ian Morrison,Girish Muddegowda,Sharon Muzerengi,Donald Pang,Gopinath Periyasamy,Gavin Preston,Naomi Priestley,Lydia Revicka,Sadia Saber,Elliott Smith,Youssef Sorour,Oliver Spooner,Jon Stone,Laszlo Sztriha,Narmathey Thambirajah,Rhys Thomas,David Veale,Jasmine Wall,Sarah White,James White,Syarah Yusoff,Laura Zambreanu

Abstract:Background: A new syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) has emerged as a rare side-effect of vaccination against COVID-19. Cerebral venous thrombosis is the most common manifestation of this syndrome but, to our knowledge, has not previously been described in detail. We aimed to document the features of post-vaccination cerebral venous thrombosis with and without VITT and to assess whether VITT is associated with poorer outcomes. Methods: For this multicentre cohort study, clinicians were asked to submit all cases in which COVID-19 vaccination preceded the onset of cerebral venous thrombosis, regardless of the type of vaccine, interval between vaccine and onset of cerebral venous thrombosis symptoms, or blood test results. We collected clinical characteristics, laboratory results (including the results of tests for anti-platelet factor 4 antibodies where available), and radiological features at hospital admission of patients with cerebral venous thrombosis after vaccination against COVID-19, with no exclusion criteria. We defined cerebral venous thrombosis cases as VITT-associated if the lowest platelet count recorded during admission was below 150 × 109 per L and, if the D-dimer was measured, the highest value recorded was greater than 2000 μg/L. We compared the VITT and non-VITT groups for the proportion of patients who had died or were dependent on others to help them with their activities of daily living (modified Rankin score 3-6) at the end of hospital admission (the primary outcome of the study). The VITT group were also compared with a large cohort of patients with cerebral venous thrombosis described in the International Study on Cerebral Vein and Dural Sinus Thrombosis. Findings: Between April 1 and May 20, 2021, we received data on 99 patients from collaborators in 43 hospitals across the UK. Four patients were excluded because they did not have definitive evidence of cerebral venous thrombosis on imaging. Of the remaining 95 patients, 70 had VITT and 25 did not. The median age of the VITT group (47 years, IQR 32-55) was lower than in the non-VITT group (57 years; 41-62; p=0·0045). Patients with VITT-associated cerebral venous thrombosis had more intracranial veins thrombosed (median three, IQR 2-4) than non-VITT patients (two, 2-3; p=0·041) and more frequently had extracranial thrombosis (31 [44%] of 70 patients) compared with non-VITT patients (one [4%] of 25 patients; p=0·0003). The primary outcome of death or dependency occurred more frequently in patients with VITT-associated cerebral venous thrombosis (33 [47%] of 70 patients) compared with the non-VITT control group (four [16%] of 25 patients; p=0·0061). This adverse outcome was less frequent in patients with VITT who received non-heparin anticoagulants (18 [36%] of 50 patients) compared with those who did not (15 [75%] of 20 patients; p=0·0031), and in those who received intravenous immunoglobulin (22 [40%] of 55 patients) compared with those who did not (11 [73%] of 15 patients; p=0·022). Interpretation: Cerebral venous thrombosis is more severe in the context of VITT. Non-heparin anticoagulants and immunoglobulin treatment might improve outcomes of VITT-associated cerebral venous thrombosis. Since existing criteria excluded some patients with otherwise typical VITT-associated cerebral venous thrombosis, we propose new diagnostic criteria that are more appropriate. Funding: None.

Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination a Vascular Liver Disease Group (VALDIG) initiative

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency

Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination

Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis

Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story

Whole Exome Sequencing in Vaccine‐Induced Thrombotic Thrombocytopenia (VITT)

Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

Understanding vaccine-induced thrombotic thrombocytopenia (VITT)

Damage-associated cellular markers in the clinical and pathogenic profile of vaccine-induced immune thrombotic thrombocytopenia

ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review

A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021

COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications

Estimating the Effect of Coronavirus Disease 2019 (COVID-19) Vaccination and Infection Variant on Post-COVID-19 Venous Thrombosis or Embolism Risk

Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19

Subsequent Vaccination against SARS-CoV-2 after Vaccine-Induced Immune Thrombotic Thrombocytopenia

Extensive thrombosis after COVID-19 vaccine: cause or coincidence?

Fc γ RIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation

Severe Thrombocytopenia, Thrombosis and Anti-PF4 Antibody after Pfizer-BioNTech COVID-19 mRNA Vaccine Booster-Is It Vaccine-Induced Immune Thrombotic Thrombocytopenia?